Gilad Oren, the President and CEO of Aprea Therapeutics, Inc. (NASDAQ:APRE), recently acquired 250 shares of the company's common stock. The shares were purchased at a price of $2.90 each, totaling $725. Following this transaction, Oren holds 332,895 shares directly. Additionally, Oren's indirect holdings include 1,200 shares owned by his daughter and 600 shares owned by his son. It is noted that Oren disclaims beneficial ownership of the shares held by his children.
InvestingPro Insights
Gilad Oren's recent purchase of Aprea Therapeutics shares comes at a time when the company's stock has experienced significant volatility. According to InvestingPro data, APRE has seen a substantial 19.14% return over the last week, despite a 47.86% decline over the past six months. This recent uptick might align with Oren's decision to increase his stake in the company.
InvestingPro Tips highlight that Aprea Therapeutics holds more cash than debt on its balance sheet, which could be seen as a positive sign for the company's financial stability. However, the company is also quickly burning through cash, a factor that investors should consider when evaluating the stock's potential.
The company's market capitalization stands at $16.57 million, reflecting its current valuation in the market. With a price-to-book ratio of 0.65, the stock may be trading below its book value, potentially indicating an undervaluation.
It's worth noting that analysts do not anticipate the company to be profitable this year, as indicated by another InvestingPro Tip. This aligns with the reported operating income margin of -1112.69% for the last twelve months, suggesting significant challenges in achieving profitability in the near term.
For investors seeking a more comprehensive analysis, InvestingPro offers additional insights with 11 more tips available for Aprea Therapeutics. These tips could provide valuable context for understanding the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.